Description

3-Quinolinecarboxylic Acid, 1-Cyclopropyl-7-[4-[2-(2,3-Dihydro-1H-Inden-5-Yl)Acetyl]-1-Piperazinyl]-6-Fluoro-1,4-Dihydro-4-Oxo- is a complex, high-purity pharmaceutical intermediate with a defined heterocyclic structure. This compound matters for its critical role as a key building block in the synthesis of advanced active pharmaceutical ingredients (APIs), particularly within the fluoroquinolone antibiotic class. It is essential for pharmaceutical R&D departments and fine chemical manufacturers engaged in developing next-generation antibacterial agents, where precise molecular architecture is paramount for efficacy and safety.

Application

• Pharmaceutical Intermediate: Primary use as a sophisticated building block in the synthesis of novel fluoroquinolone antibiotics.
• Antibacterial Drug Research: Serves as a core scaffold in medicinal chemistry programs targeting DNA gyrase and topoisomerase IV inhibition.
• Process Chemistry Development: Used in route scouting and optimization for the commercial-scale production of complex API molecules.
• Reference Standard: Employed as a high-purity analytical standard for quality control and regulatory submissions in pharmaceutical manufacturing.
• Chemical Biology Studies: Utilized as a probe or precursor in biochemical research to study bacterial resistance mechanisms.
• Custom Synthesis: A starting material for the contract synthesis of specialized, non-commercial chemical entities for preclinical studies.

Basic Information

Product Name	3-Quinolinecarboxylic Acid, 1-Cyclopropyl-7-[4-[2-(2,3-Dihydro-1H-Inden-5-Yl)Acetyl]-1-Piperazinyl]-6-Fluoro-1,4-Dihydro-4-Oxo-
CAS No.	1054011-63-0
Molecular Formula	C28H28FN3O4
Molecular Weight	489.54 g/mol
Synonyms	1-Cyclopropyl-7-[4-[2-(2,3-dihydro-1H-inden-5-yl)acetyl]-1-piperazinyl]-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-[4-[2-(2,3-dihydro-1H-inden-5-yl)acetyl]-1-piperazinyl]-4-oxo-3-quinolinecarboxylic acid; 1054011-63-0; UNII-9J97361D4F; 9J97361D4F; CHEMBL3183455; BDBM50157857; AKOS025147623.
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency for critical pharmaceutical applications. Quality is verified through comprehensive analytical methods including HPLC, NMR, and mass spectrometry to confirm identity, purity, and impurity profiles. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting compliance with agreed specifications. We support our partners in meeting the stringent requirements of cGMP and ICH guidelines for pharmaceutical development.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (typically 15-25°C). The container should be kept in a well-ventilated area and protected from moisture. For long-term storage, consider inert gas purging.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Conforms to reference
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity	≤ 0.5%
Total Impurities	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.